Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Characterization of Comorbid Post-traumatic Stress Disorder and Major Depressive Disorder Utilizing Ketamine as an Experimental Medicine Probe


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04032301

Organisation Name: University of Minnesota

Overal Status: Recruiting

Start Date: September 30, 2019

Last Update: September 4, 2020

Lead Sponsor: University of Minnesota

Brief Summary: Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability. Veterans with both PTSD and MDD (PTSD+MDD) have been shown to be at much greater suicidal risk than individuals with only one of these disorders. Ketamine given as repeated infusions has been shown to be effective in rapidly reducing PTSD and MDD symptoms in treatment resistant PTSD+MDD individuals. However, knowledge about the mechanisms underlying comorbid PTSD and MDD remain limited. The purpose of this study is to use repeated ketamine infusions as a probe to validate a model of PTSD+MDD that focuses on neuroanatomy and executive functioning.

Conditions:
  • Post-Traumatic Stress Disorders
  • Major Depressive Disorder


Total execution time in seconds: 0.19846987724304